LDL-cholesterol
LDL cholesterol lowering, PCSK9 and neurocognitive effects?
The possibility of neurocognitive effects with low-density lipoprotein (LDL) cholesterol lowering has been much debated. A new study (1) raises this issue again, suggesting increased risk of memory loss during the 30 days following the start of treatment, when comparing statin users and nonusers of…
read more »
LDL treatment choices in everyday practice too conservative
Results from a survey of more than 1,500 patients showed that physicians are too cautious in managing low-density lipoprotein (LDL) cholesterol in high cardiovascular risk patients, even when they are not at goal. The findings are particularly relevant in the light of recent favourable opinions…
read more »
Safety of lowering LDL-C
Dr Albert Wiegman discusses the safety of lowering LDL C in FH children
read more »
Does the mechanism of lowering LDL cholesterol matter? Insights from recent Mendelian Randomization studies
Meta-analyses of numerous randomized trials have demonstrated that lowering low density lipoprotein (LDL) cholesterol by inhibiting HMG-CoA reductase (HMGCR) with a statin reduces the risk of major cardiovascular events by approximately 20% for each mmol/L lower LDL cholesterol.1 However, several randomized trials have failed to…
read more »
Heterogeneity in FH: What are the implications for management?
According to Professor Frederick Raal, South Africa, irrespective of genotype, what matters is reducing the LDL-C burden with lipid-lowering therapy. Familial hypercholesterolemia (FH) is an autosomal co-dominant disorder usually resulting from mutations in the LDL receptor (LDLR) gene characterised by elevated levels of LDL-cholesterol (LDL-C)…
read more »
